

Evidence dossier - John Armitage - Egerton Capital

GetCoattail manager profile: <https://getcoattail.com/manager/john-armitage-egerton-capital> | CIK 0001581811 | Rank #45 of 149 tracked managers by reported 13F value.

Background: Founded: 1994 | HQ: London, England, United Kingdom | Style: Equity long/short and equity long-only strategies using fundamental, research-intensive stock selection | Key person: John Armitage

Background source: https://en.wikipedia.org/wiki/Egerton_Capital

1. Latest filing snapshot (as reported)

Period end: 2026-06-30 Filed: 2026-07-21 Reported total value: \$10.4B Positions: 23 Top-10 concentration: 76.0% of reported value.

Ticker	Company	Weight	Reported value
V	Visa Inc	14.13%	\$1.5B
GOOG	Alphabet Inc	11.24%	\$1.2B
APH	Amphenol Corp	8.29%	\$858M
AMZN	Amazon Com Inc	8.23%	\$852M
MCO	Moodys Corp	7.46%	\$772M
NVDA	Nvidia Corporation	6.61%	\$684M
MDLN	Medline Inc	6.28%	\$650M
VMC	Vulcan Matls Co	5.62%	\$582M
CRH	Crh Plc	4.53%	\$469M
AMAT	Applied Matls Inc	3.64%	\$377M

2. Hypothetical 13F-clone results

Window: 2016-11-03 to 2026-10-02 (40 filings). Cumulative: +293.2% CAGR: +14.82% SPY same window: cumulative +331.7%, CAGR +15.90%. Trailing CAGR - 10Y: n/a, 5Y: +8.37%, 3Y: +16.56%, 1Y: +4.68%. Max drawdown (month-end, approximate): -29.7%.

Method (summary): For each Form 13F filing in the history table, the clone takes the positions and weights exactly as disclosed (reported values at the period end). From the filing date until the next filing date, each position earns the return of its dividend-adjusted closing price (Yahoo Finance daily bars; split- and dividend-adjusted). At each new filing the clone rebalances to the newly disclosed weights. Positions that cannot be priced (non-U.S. listings, some recent IPOs and delisted names) are excluded from both the weights and the returns, and the covered share of reported value is stated in this dossier. The benchmark is SPY on the same dividend-adjusted basis over the identical window. Month-end values are used for drawdown and trailing-window statistics and are approximate.

3. Filing history - every clone input

Each row is one SEC Form 13F filing used by the clone. Accession numbers link to the filing index at sec.gov: <https://www.sec.gov/Archives/edgar/data/<CIK>/<accession without dashes>/<accession>-index.htm>

Quarter	Accession no.	Filed	CUSIPs
2016Q3	0001581811-16-000003	2016-11-03	26
2016Q4	0001581811-17-000002	2017-02-14	27
2017Q1	0001581811-17-000003	2017-05-09	25
2017Q2	0001581811-17-000005	2017-07-28	31
2017Q3	0001581811-17-000007	2017-11-03	32
2017Q4	0001581811-18-000002	2018-02-08	32
2018Q1	0001581811-18-000003	2018-05-11	32

2018Q2	0001581811-18-000004	2018-08-07	31
2018Q3	0001581811-18-000005	2018-11-13	27
2018Q4	0001581811-19-000002	2019-02-12	26
2019Q1	0001581811-19-000003	2019-05-09	26
2019Q2	0001581811-19-000005	2019-08-13	31
2019Q3	0000919574-19-006859	2019-11-13	33
2019Q4	0001581811-20-000003	2020-02-13	33
2020Q1	0001581811-20-000004	2020-05-13	26
2020Q2	0001581811-20-000005	2020-08-12	28
2020Q3	0001581811-20-000006	2020-11-09	35
2020Q4	0001581811-21-000003	2021-02-12	34
2021Q1	0001581811-21-000005	2021-05-17	35
2021Q2	0001581811-21-000006	2021-08-12	31
2021Q3	0001581811-21-000007	2021-11-08	34
2021Q4	0001581811-22-000003	2022-02-11	32
2022Q1	0001581811-22-000004	2022-05-09	29
2022Q2	0001581811-22-000007	2022-08-09	26
2022Q3	0001581811-22-000008	2022-11-10	23
2022Q4	0001581811-23-000002	2023-02-07	21
2023Q1	0001581811-23-000004	2023-05-09	25
2023Q2	0001581811-23-000005	2023-08-10	23
2023Q3	0001581811-23-000006	2023-11-13	22
2023Q4	0001581811-24-000003	2024-02-12	22
2024Q1	0001581811-24-000004	2024-05-13	22
2024Q2	0001581811-24-000007	2024-08-13	26
2024Q3	0001581811-24-000009	2024-11-05	30
2024Q4	0001581811-25-000004	2025-02-10	30
2025Q1	0001581811-25-000005	2025-05-06	27
2025Q2	0001581811-25-000007	2025-08-12	25
2025Q3	0001581811-25-000010	2025-11-12	24
2025Q4	0001581811-26-000002	2026-02-11	23
2026Q1	0001581811-26-000005	2026-05-13	24
2026Q2	0001581811-26-000007	2026-07-21	23

4. Coverage and adjustments

Price coverage at the latest filing: 94.0% of reported value is covered by our price history and included in the clone; the rest is excluded (mostly non-U.S. listings, recent IPOs, delisted names).

5. Disclaimer

This document and the associated web profile present a hypothetical replication ("13F clone") of the long U.S. equity positions disclosed on Form 13F. It is not the named fund's actual investment return: Form 13F excludes short positions, bonds, cash, non-U.S. listings, private holdings, leverage and fees, and positions are only observable quarterly, with a filing lag of up to 45 days. Nothing here is investment advice or a recommendation. Past hypothetical performance does not guarantee future results.